Matinas Biopharma Holdings, Inc. · AMEX:MTNB

Matinas Biopharma — Q3 2022 Earnings Presentation

24 slides from Matinas Biopharma's earnings presentation, Nov 2, 2022

1. Slide 1: Q3 2022 Results Call Presentation

   Q3 2022 Results Call Presentation November 2, 2022 MATINAS BIOPHARMA

2. Slide 2: Forward Looking Statements

   Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, cash flow and other sta

3. Slide 3: Matinas Has Executed on Multiple Milestones... With More to Come

   Matinas Has Executed on Multiple Milestones...... With More to Come MAT2203 LNC Platform & Collaborations NNN NANA 1H 2022 Milestones & Catalysts FDA approval on Phase 3 of EnACT Initiate preclinical studies in C. auris and mucormycosis Data available from Phase 1 SAD study in healthy volunteers Ini

4. Slide 4: MAT2203

   MAT2203 ORAL AMPHOTERICIN B Phase 3 to Commence Q1 2023 BIOPHARMA

5. Slide 5: MAT2203: Unmet Medical Need in Invasive Fungal Infections

   MAT2203: Unmet Medical Need in Invasive Fungal Infections In October 2022, The World Health Organization (WHO) released its first fungal priority pathogens list to guide research and development* Matinas is leveraging the safety and efficacy of MAT2203 to meet the needs of both critical and high pri

6. Slide 6: MAT2203: Unmet Medical Need in Invasive Fungal Infections

   MAT2203: Unmet Medical Need in Invasive Fungal Infections Available systemically and orally elt ws Potent - STCCUNG| a o Fungicidal THE IDEAL Penevates welllints QO ANTIFUNGAL ) Well-tolerated infected tissues * r and safe AGEI and safe A\ & 4 $ . Minimal drug-drug Cu @ Low propensity for interactio

7. Slide 7: Cryptococcal Meningitis Is a Severe Fungal Infection with High Mortality

   Cryptococcal Meningitis Ils a Severe Fungal Infection with High Mortality Deadly invasive fungal infection of the brain Typically affects immunocompromised individuals 10-20% 7,200 of all HIV-related Estimated incidence in deaths US and E5 combined 180,000 deaths per year worldwide Mortality VERY HI

8. Slide 8: MAT2203: EnACT, a Successful Phase 2 Study

   MAT2203: EnACT, a Successful Phase 2 Study EnACT INDUCTION (2 WEEKS) EARLY CONSOLIDATION (4 WEEKS) MAT2203 MAT2203 + Fluconazole @ conortt = DED Feel 5 days 10 days MAT2203 MAT2203 + Fluconazole (n=40) 2 days 13 days MAT2203 MAT2203 + Fluconazole @ COHORTS VAMB Mar2203 (n=10) 5 days 10 days MAT2203

9. Slide 9: Cohort 2 and Cohort 4 Key Secondary Efficacy Endpoint: Survival

   Cohort 2 and Cohort 4 Key Secondary Efficacy Endpoint: Survival ™MAT2203 Cohort 2 ™MAT2203 Cohort 4 =SoC 100 4 93 80 4 gS 604 8 = 404 no 20 4 Oo T T Week 2 Week 10 Week 18 Primary Endpoint Secondary Endpoint (Phase 3) (Phase 3) n/N= 39/40? 38/40 38/40 39/402 37/40" 35/40 38/402 36/40* 34/40 36/40? 3

10. Slide 10: MAT2203 Met the Primary Endpoint (EFA) in Both Cohorts

    MAT2203 Met the Primary Endpoint (EFA) in Both Cohort 2 (step down) and 4 (all oral) ENACT EFA Comparisons Treatment EFAs > 0.2are associated with /ower mortality and improved clinical outcomes. Beyond a 0.2threshold, no incremental benefits have been : 1 Concurrent Controls (Cohorts 1-4) : ——_A— 5

11. Slide 11: MAT2203 Cohort Antifungal Activity

    MAT2203 Cohort 4 Antifungal Activity Examples of Noteworthy Antifungal Activity in Patients with High Baseline Counts i 1 Treatment: Intervention Q 2 | Treatment: Intervention QCC Result QCC Result (CFU/mL) 715,000 120,000 2550 705 (CFU/mL) 100,000 42,500 40 o oe oe e e oe eo VISIT DAY Screening Day

12. Slide 12: EnACT: Cohort 4 Results

    EnACT : Cohort 2 Results (Phase 3 Design Replicates Cohort 2) ENACT Clinical Data Validates the Use of the LNC Platform to Enable Oral Administration and Overcome Toxicity — ee — e e e e e F All patients completin MAT2203 was safe and Exceeded the primary P 7 1p é No breakthrough e a . induction ach

13. Slide 13: Phase III Pivotal Study Design - To Initiate Q1 2023

    Phase III Pivotal Study Design - To Initiate Q1 2023 (Replicates Cohort 2 of EnACT) Assess MAT2203 as step-down therapy after 2 days of IV AMB for the Treatment of Cryptococcal Meningitis Validate results observed in EnACT Randomized 1:1:4 ratio to 1 of 2 MAT2203 arms or SoC SCREENING TREATMENT 1 1

14. Slide 14: Value Proposition for MAT2203

    Value Proposition for MAT2203 Ore ministration Lack enables earlier release enables longer treatment duration from hospital or avoidance supported by oral of home infusion administration ANAGEM cecal ion Prophylaxis in : Transplant Patients Overall Development Strategy: Cryptococcal meningitis is a

15. Slide 15: MAT2203: Potential for Treating Mucormycosis

    MAT2203: Potential for Treating Mucormycosis Mucormycosis A life-threatening infection commonly caused by Rhizopus species, (Black Fungus) seen in immunocompromised patients, with mortality rates >50% to 100% Lung and Brain Fungal Knockdown in R. delemar ii cor MICs in R. delemar Current Approved Rx

16. Slide 16: MAT2203: Addressing a $550M+ Market with Active Regional and Global Pharma

    MAT2203: Addressing a $550M+ Market with Active Regional and Global Pharma CIDARA oD SCYNEXIS HANSOH THERAPEUTICS M AT2 20. 3 September 2019 February 2022 Cidara licenses ex-US / ex-Japan rights Scynexis licenses Greater China rights of of rezafungin to Mundipharma Ibrexafungorpis to Hansoh Planned

17. Slide 17: The LNC Platform

    The LNC Platform COPYRIGHT MATINAS BIOPHARMA - 2022

18. Slide 18: Lipid Nanocrystal (LNC) Platform: Clinically Validated Intracellular Delivery

    Lipid Nanocrystal (LNC) Platform: Clinically Validated Intracellular Delivery Next generation delivery - beyond LNPs and viral vectors Extra-hepatic Targeting Primary component (phosphatidylserine) facilitates preferential cellular uptake Demonstrated uptake by phagocytes and cells with externalized

19. Slide 19: Phosphatidylserine Enables Intracellular Delivery

    Phosphatidylserine Enables Intracellular Delivery Cell membrane Normally, PS is confined to the inner layer (facing cytosol) flammation Inju Cell membrane With “activation” PS moves from the inner layer to the outer layer (cell membrane) LNCs achieve effective intracellular delivery via BOTH phagocy

20. Slide 20: Matinas' Pipeline and Discovery Programs: Internal and Collaborative

    Matinas’ Pipeline and Discovery Programs: Internal and Collaborative Program Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Collaborators Crypt ! MAT2203, Phase 3 to Commence Q1 2023 LNC-Amphotericin B i j (oral) In vivo studies ongoing MAT2501 Non-tuberculous - . = -aa® LNC-Amikacin mycob

21. Slide 21: Unlocking the Full Potential of the LNC Platform

    Unlocking the Full Potential of the LNC Platform Matinas is working internally and with third parties to push the boundaries of LNC delivery Intracellular Delivery of Nucleic Acids siRNA Past Oral Formulations of Anti-Infectives MAT2203 MAT2501 A ASO mRNA DNA =O Broad Therapeutic Applications Infect

22. Slide 22: Bandwidth to Execute on Multiple Milestones

    Bandwidth to Execute on Multiple Milestones Financial Summary Capitalization Summary Analyst Coverage AN Shares 0/S 216.86M * Robert (Bert) Hazlett H . mi\\ Runway into 2024 Stock Options* 27.782M BTIG Warrants* .988M (weighted A . ae ndrew S. Fein $33.1M* in Cash, Cash CSHB COE) H.C, Wainwright Equ

23. Slide 23: Matinas Has Executed on Multiple Milestones...... With More to Come

    Matinas Has Executed on Multiple Milestones...... With More to Come MAT2203 LNC Platform & Collaborations NNN NANA 1H 2022 Milestones & Catalysts FDA approval on Phase 3 of EnACT Initiate preclinical studies in C. auris and mucormycosis Data available from Phase 1 SAD study in healthy volunteers Ini

24. Slide 24: Matinas BioPharma Holdings

    Matinas BioPharma Holdings (NYSE AMER: MTNB) 1545 Route 206 South Suite 302 Bedminster, NJ 07921 (908) 484-8805 www.matinasbiopharma.com MATINAS BIOPHARMA

Matinas BioPharma Holdings — Q3 2022 Earnings Presentation on 6ix